Depo-Provera vs. Ozempic Lawsuit: Key Differences Explained

Last Updated: March 26, 2026

The Depo-Provera meningioma lawsuit and the GLP-1/Ozempic lawsuit are two of the largest pharmaceutical litigations in the United States. Both involve widely prescribed medications linked to serious injuries that manufacturers allegedly failed to warn about — but the drugs, injuries, and litigation timelines differ significantly.

Drug Type and Mechanism

These two litigations involve fundamentally different categories of medication. Depo-Provera is an injectable hormonal contraceptive containing medroxyprogesterone acetate, a synthetic progestin administered every three months. It has been on the U.S. market since 1992 and has been used by millions of women for birth control. The GLP-1 receptor agonists — including Ozempic, Wegovy, Mounjaro, Trulicity, Saxenda, and Rybelsus — are a newer class of drugs originally developed for type 2 diabetes and increasingly prescribed for weight management. These medications work by mimicking the incretin hormone GLP-1 to regulate blood sugar and appetite.

Nature of Injuries

The injuries at the center of each lawsuit are dramatically different. In the Depo-Provera litigation, plaintiffs allege that prolonged use of the contraceptive caused meningiomas — typically benign but potentially debilitating brain tumors that can require surgery, cause neurological symptoms, and in some cases prove life-threatening. A 2024 BMJ study found that prolonged Depo-Provera use was associated with a significantly elevated meningioma risk. In the GLP-1 litigation, the injuries are primarily gastrointestinal — gastroparesis, bowel obstruction, gallbladder disease, pancreatitis, and NAION (vision loss).

FDA Regulatory History

The FDA’s response to each drug class reflects different regulatory timelines. For Depo-Provera, the FDA added a black box warning in 2024 regarding meningioma risk after decades of use without such a warning — a central allegation in the litigation is that Pfizer knew or should have known about the risk far earlier. For GLP-1 drugs, the FDA updated Ozempic’s label in 2023 to include language about ileus (a form of intestinal blockage), and further labeling changes have followed as adverse event reports accumulated through the FAERS database.

Litigation Timeline and Structure

Both cases are consolidated as multidistrict litigations (MDLs) in the Eastern District of Pennsylvania, but at different stages. The GLP-1 MDL (3094) was established earlier and has a larger case count, with thousands of plaintiffs. The Depo-Provera MDL (3127) is newer with hundreds of cases, though filings are accelerating. Both MDLs are working through the bellwether selection process, and neither has reached a global settlement as of March 2026. For Depo-Provera claimants, the discovery rule is particularly important because meningiomas can take years or even decades to develop and be diagnosed.

Who Qualifies for Each Lawsuit

The eligibility criteria differ based on the drug and injury:

• Depo-Provera lawsuit: You received Depo-Provera injections and were later diagnosed with a meningioma (brain tumor). Duration of use and timing of diagnosis are key factors.
• GLP-1/Ozempic lawsuit: You took any GLP-1 receptor agonist and developed gastroparesis, bowel obstruction, gallbladder disease, pancreatitis, NAION, or other serious gastrointestinal injury. See our eligibility guide for a full breakdown.

Frequently Asked Questions

Can I file a claim in both lawsuits?

Yes, if you used both Depo-Provera and a GLP-1 medication and suffered injuries from each, these are separate claims involving different drugs, manufacturers, and injuries. Each claim would be evaluated independently.

Which lawsuit is further along?

The GLP-1 MDL (3094) is further along in terms of case count and pretrial proceedings. However, both MDLs are in relatively early stages, with bellwether trial preparation underway and no settlements reached as of early 2026.

Do I need the same type of attorney for both?

Both lawsuits are pharmaceutical product liability cases, so attorneys experienced in mass tort litigation can handle either. However, the medical evidence and expert requirements differ — meningioma cases involve neurosurgical expertise, while GLP-1 cases involve gastroenterology.

How long do these lawsuits typically take?

Pharmaceutical MDLs generally take several years from consolidation to resolution. Bellwether trials provide early data points that can influence settlement negotiations, but individual timelines vary based on case complexity and court scheduling.

Take the Next Step

Whether you were harmed by Depo-Provera or a GLP-1 medication like Ozempic, understanding which litigation applies to your situation is the first step. Both lawsuits are actively accepting new claims.

If you or a loved one has been affected, request a free case review today.

Advertisement. This content is provided for informational purposes only and does not constitute legal advice. NuLegal | Ashkaan Hassan, Esq. | CA Bar #283629